Literature DB >> 16507423

Percutaneous coronary interventions with stents in cardiac transplant recipients.

Feras M Bader1, Abdallah G Kfoury, Edward M Gilbert, William H Barry, Naeem Humayun, Mary E Hagan, Heidi Thomas, Dale Renlund.   

Abstract

BACKGROUND: Allograft coronary vasculopathy is a major cause of death beyond the first year after cardiac transplantation. The aim of this study was to review our experience with percutaneous coronary intervention (PCI) with stents in cardiac transplant recipients.
METHODS: We identified patients who were treated with PCI using stents. Patient characteristics, procedure information and clinical outcomes were assessed for these patients by review of their medical records. We also compared results for those who had bare metal stents vs those who had drug-eluting stents.
RESULTS: Forty patients from our program's 865 cardiac transplant recipients received a total of 78 coronary stents. There were 35 males (87.5%) and 5 females (12.5%). The indication for PCI was progressive asymptomatic coronary vasculopathy in 18 patients (45%), angina in 5 (12.5%), acute myocardial infarction (MI) in 4 (10%) and congestive heart failure (CHF) in 6 (15%). Primary success (<50% residual stenosis) was obtained in 71 (91%) of 78 stents. During the mean follow-up of 40.8 +/- 34.5 months, 6 patients died (15%) and 2 (5%) were re-transplanted. There was a lower rate of re-stenosis with drug-eluting stents (2 of 13, 15%) compared with bare metal stents (20 of 65, 31%), although this difference was not statistically significant (p = 0.27).
CONCLUSIONS: In cardiac transplant recipients, PCI with stents can be performed with high rates of primary success. Restenosis rates are higher compared with PCI in native coronary arteries. A trend toward less restenosis with drug-eluting stents was observed, which needs to be confirmed in larger studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507423     DOI: 10.1016/j.healun.2005.09.016

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.

Authors:  Michele Pighi; Fabrizio Tomai; Alessandro Petrolini; Leonardo de Luca; Giuseppe Tarantini; Alberto Barioli; Paola Colombo; Silvio Klugmann; Marco Ferlini; Maurizio Ferrario Ormezzano; Bruno Loi; Paolo Calabrò; Renato Maria Bianchi; Giuseppe Faggian; Alberto Forni; Corrado Vassanelli; Marco Valgimigli; Flavio Ribichini
Journal:  J Cardiovasc Transl Res       Date:  2015-12-18       Impact factor: 4.132

2.  New developments for the detection and treatment of cardiac vasculopathy.

Authors:  Kevin J Clerkin; Ziad A Ali; Donna M Mancini
Journal:  Curr Opin Cardiol       Date:  2017-02-15       Impact factor: 2.161

Review 3.  Diagnosis and management of coronary allograft vasculopathy in children and adolescents.

Authors:  Nathalie Dedieu; Gerald Greil; James Wong; Matthew Fenton; Michael Burch; Tarique Hussain
Journal:  World J Transplant       Date:  2014-12-24

4.  Coronary collaterals predict improved survival and allograft function in patients with coronary allograft vasculopathy.

Authors:  Kory J Lavine; Marc Sintek; Eric Novak; Gregory Ewald; Edward Geltman; Susan Joseph; John Pfeifer; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2013-05-24       Impact factor: 8.790

5.  Evolving concepts and treatment strategies for cardiac allograft vasculopathy.

Authors:  Rodolfo Denadai Benatti; David O Taylor
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-01

Review 6.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

Review 7.  Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients.

Authors:  Jessica G Y Luc; Jae Hwan Choi; Syed-Saif Abbas Rizvi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; Gordon R Reeves; Andrew J Boyle; John W Entwistle; Rohinton J Morris; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2018-01

Review 8.  Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis.

Authors:  Syed-Saif Abbas Rizvi; Jessica G Y Luc; Jae Hwan Choi; Kevin Phan; Ester Moncho Escrivà; Sinal Patel; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2018-01

9.  ST-elevation acute coronary syndrome in a patient after heart transplant.

Authors:  Aldona Browarek; Artur Dębski; Paweł Tyczyński; Małgorzata Piotrowska; Tomasz Zieliński; Małgorzata Sobieszczańska-Małek; Maciej Karcz; Adam Witkowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-03-23       Impact factor: 1.426

10.  Coronary Interventions in Pediatric Congenital Heart Disease.

Authors:  Anastasia Schleiger; Peter Kramer; Stephan Dreysse; Stephan Schubert; Björn Peters; Joachim Photiadis; Felix Berger; Johannes Nordmeyer
Journal:  Pediatr Cardiol       Date:  2021-12-13       Impact factor: 1.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.